Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis in New Onset Neovascular Glaucoma
NCT00727038Phase 2Withdrawn
- Sponsor
- University of Illinois Chicago
- Start
- Jan 2008
- Primary completion
- May 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ranibizumab in neovascular glaucoma (NVG), sponsored by University of Illinois Chicago. Planned start Jan 2008; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT00727038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00727038.